Affiliation:
1. School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore
Abstract
Antibody–drug Conjugates (ADCs) are a powerful therapeutic modality for cancer treatment. ADCs are multi-functional biologics in which a disease-targeting antibody is conjugated to an effector payload molecule via a linker. The success of currently used ADCs has been largely attributed to the development of linker systems, which allow for the targeted release of cytocidal payload drugs inside cancer cells. Many lysosomal proteases are over expressed in human cancers. They can effectively cleave a variety of peptide sequences, which can be exploited for the design of ADC linker systems. As a well-established linker, valine-citrulline-p-aminobenzyl carbamate (ValCitPABC) is used in many ADCs that are already approved or under preclinical and clinical development. Although ValCitPABC and related linkers are readily cleaved by cathepsins in the lysosome while remaining reasonably stable in human plasma, many studies have shown that they are susceptible to carboxylesterase 1C (Ces1C) in mouse and rat plasma, which hinders the preclinical evaluation of ADCs. Furthermore, neutropenia and thrombocytopenia, two of the most commonly observed dose-limiting adverse effects of ADCs, are believed to result from the premature hydrolysis of ValCitPABC by human neutrophil elastase. In addition to ValCitPABC, the GGFG tetrapeptidyl-aminomethoxy linker is also cathepsin-cleavable and is used in the highly successful ADC drug, DS8201a. In addition to cathepsin-cleavable linkers, there is also growing interest in legumain-sensitive linkers for ADC development. Increasing plasma stability while maintaining lysosomal cleavability of ADC linkers is an objective of intensive current research. This review reports recent advances in the design and structure–activity relationship studies of various peptide/peptidomimetic linkers in this field.
Funder
Singapore Ministry of Education
National Research Foundation (NRF) under the Prime Minister’s Office, Singapore
Subject
General Biochemistry, Genetics and Molecular Biology,Medicine (miscellaneous)
Reference55 articles.
1. Antibody drug conjugate: The “biological missile” for targeted cancer therapy;Fu;Signal Transduct Target. Ther.,2022
2. Tong, J.T., Harris, P.W., Brimble, M.A., and Kavianinia, I. (2021). An insight into FDA approved antibody-drug conjugates for cancer therapy. Molecules, 26.
3. Drawing lessons from the clinical development of antibody-drug conjugates;Lyon;Drug Discov. Today Technol.,2018
4. Antibody–drug conjugates for cancer;Chau;Lancet,2019
5. Strategies and challenges for the next generation of antibody–drug conjugates;Beck;Nat. Rev. Drug Discov.,2017
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献